Merck & Company Inc (MRK)vsNexalin Technology Inc. (NXL)
MRK
Merck & Company Inc
$129.56
+3.34%
HEALTHCARE · Cap: $283.78B
NXL
Nexalin Technology Inc.
$0.36
+1.39%
HEALTHCARE · Cap: $7.78M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 23865203% more annual revenue ($65.77B vs $275,580). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
NXL
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-60.0%
Fair Value
$80.96
Current Price
$129.56
$48.60 premium
Intrinsic value data unavailable for NXL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -319.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : NXL
The strongest argument for NXL centers on Price/Book.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : NXL
The primary concerns for NXL are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NXL carries more volatility with a beta of 3.83 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 18/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Nexalin Technology Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Nexalin Technology Inc. is an innovative leader in the medical technology sector, focused on revolutionizing the treatment landscape for neurological and psychiatric disorders through its proprietary transcranial electrical stimulation devices. The company’s non-invasive therapies address critical mental health challenges, including anxiety, depression, and substance addiction, underscoring its dedication to enhancing patient outcomes and advancing mental health solutions. With a solid foundation in research and a strategic emphasis on leveraging burgeoning demand for advanced healthcare innovations, Nexalin is poised for significant growth in the evolving digital health marketplace, making it an attractive prospect for institutional investors.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?